Zydus Life Share Price Up on Dr. Reddy’s Partnership for Pertuzumab Biosimilar

Zydus Lifesciences share price saw a slight increase during the opening trade on July 1, following the announcement of a licensing agreement with Dr. Reddy's Laboratories to co-market a Pertuzumab biosimilar in India. At 09:26 am IST, Zydus Lifesciences quoted ₹1,077.10, up ₹2.75, or 0.26%, on the BSE. 

Pertuzumab is an essential treatment for patients with HER2-positive breast cancer. The biosimilar has been internally developed by the research team at the Zydus Research Centre (ZRC). 

Under the terms of this agreement, Dr. Reddy’s will receive semi-exclusive rights from Zydus to co-market the product in India. 

Zydus will market the product under the brand name Sigrima, while Dr. Reddy’s will sell it under the brand name Womab. Zydus will receive upfront licensing income and may also earn milestone income contingent on the achievement of specific milestones. 

In June, the company received a report from the United States Food and Drug Administration (USFDA) regarding the inspection of its injectables manufacturing facility, conducted from March 18 to March 27, 2024, at the Pharmez Special Economic Zone in Matoda, Gujarat, India. The inspection was classified as "Official Action Indicated" (OAI).

On June 14, the company received tentative approval from the USFDA to market Azilsartan Medoxomil and Chlorthalidone Tablets, 40 mg/12.5 mg and 40 mg/25 mg.

Zydus Lifesciences Ltd, previously known as Cadila Healthcare Ltd, is an integrated global healthcare provider. The company is involved in the discovery, development, manufacturing, and commercialization of a wide range of healthcare products.

The company's product portfolio comprises active pharmaceutical ingredients (APIs), formulations, wellness products, and animal health products. Zydus Lifesciences' offerings are used in treating diseases across various therapeutic areas, including gastrointestinal, cardiovascular, respiratory, pain management, cancer, inflammation, neurology, and women's health, among others.

Zydus Lifesciences conducts research to develop biologics, biosimilars, vaccines, and new chemical entities. The company operates manufacturing facilities in Gujarat, Goa, Maharashtra, Sikkim, and Himachal Pradesh in India, as well as in Brazil and the US. It has a presence in the US, Europe, South Africa, Japan, Brazil, and other emerging markets. Zydus Lifesciences is headquartered in Ahmedabad, Gujarat, India.